Results 21 to 30 of about 2,568,874 (328)

Enhanced CDC of B cell chronic lymphocytic leukemia cells mediated by rituximab combined with a novel anti-complement factor H antibody. [PDF]

PLoS ONE, 2017
Rituximab therapy for B cell chronic lymphocytic leukemia (B-CLL) has met with mixed success. Among several factors to which resistance can be attributed is failure to activate complement dependent cytotoxicity (CDC) due to protective complement ...
Mark T Winkler, Ryan T Bushey, Elizabeth B Gottlin, Michael J Campa, Eross S Guadalupe, Alicia D Volkheimer, J Brice Weinberg, Edward F Patz   +7 more
doaj   +3 more sources

Small-molecule factor B inhibitor for the treatment of complement-mediated diseases [PDF]

Proceedings of the National Academy of Sciences of the United States of America, 2019
Significance Complement is a key component of the innate immune system; however, its dysregulation due to genetic mutations or the presence of autoantibodies can cause a number of diseases including age-related macular degeneration, paroxysmal nocturnal ...
Anna Schubart, Karen Anderson, Nello Mainolfi, Holger Sellner, Takeru Ehara, Christopher M. Adams, Aengus Mac Sweeney, Sha-Mei Liao, Maura Crowley, Amanda Littlewood‐Evans, Sophie Sarret, Grazyna Wieczorek, Ludovic Perrot, Valérie Dubost, Thierry Flandre, Yuzhou Zhang, Richard J. Smith, Antonio M. Risitano, Rajeshri G. Karki, Chun Zhang, Eric Valeur, Finton Sirockin, Bernd Gerhartz, P. Erbel, Nicola Hughes, Thomas M. Smith, Frédéric Cumin, Upendra A. Argikar, Börje Haraldsson, Muneto Mogi, Richard Sedrani, Christian Wiesmann, Bruce Jaffee, Jürgen Maibaum, Stefanie Flohr, R. A. Harrison, Jörg Eder   +36 more
openalex   +2 more sources

Activation of complement factor B contributes to murine and human myocardial ischemia/reperfusion injury. [PDF]

PLoS ONE, 2017
The pathophysiology of myocardial injury that results from cardiac ischemia and reperfusion (I/R) is incompletely understood. Experimental evidence from murine models indicates that innate immune mechanisms including complement activation via the ...
Nicholas Chun, Ala S Haddadin, Junying Liu, Yunfang Hou, Karen A Wong, Daniel Lee, Julie I Rushbrook, Karan Gulaya, Roberta Hines, Tamika Hollis, Beatriz Nistal Nuno, Abeel A Mangi, Sabet Hashim, Marcela Pekna, Amy Catalfamo, Hsiao-Ying Chin, Foramben Patel, Sravani Rayala, Ketan Shevde, Peter S Heeger, Ming Zhang   +20 more
doaj   +2 more sources

Complement factor B mutation-associated aHUS and myocardial infarction. [PDF]

BMJ Case Rep, 2017
A 6-month-old female infant was referred with a 3-day history of low-grade fever, slight nasal congestion and rhinorrhoea. On admission, the clinical findings were unremarkable and she was discharged home. However, she became progressively more listless with a decreased urine output and was once again seen in the emergency department.
Noronha N, Costa FD, Dias A, Dinis A.
europepmc   +5 more sources

Access to the Complement Factor B Scissile Bond Is Facilitated by Association of Factor B with C3b Protein* [PDF]

Journal of Biological Chemistry, 2011
Factor B is a zymogen that carries the catalytic site of the complement alternative pathway C3 convertase. During convertase assembly, factor B associates with C3b and Mg2+ forming a pro-convertase C3bB(Mg2+) that is cleaved at a single factor B site by ...
D. Hourcade, Lynne M. Mitchell
semanticscholar   +3 more sources

Inhibiting the alternative pathway of complement by reducing systemic complement factor B: Randomized, double-blind, placebo-controlled phase 1 studies with Sefaxersen

Immunobiology
An over-active alternative complement pathway has been implicated in the pathophysiology of multiple diseases, including IgA nephropathy and geographic atrophy secondary to age related macular degeneration.
Michael L. McCaleb, Steven G. Hughes, Tamar R. Grossman, Ashley Frazer-Abel, Bill Jung, Lixuan Yin, Scott P. Henry, Brett P. Monia, Eugene Schneider, Richard Geary, Gary T. Brice   +10 more
doaj   +2 more sources

Genetic coding variant in complement factor B (CFB) is associated with increased risk for perianal Crohn's disease and leads to impaired CFB cleavage and phagocytosis. [PDF]

Gut, 2023
Akhlaghpour M, Haritunians T, More SK, Thomas LS, Stamps DT, Dube S, Li D, Yang S, Landers CJ, Mengesha E, Hamade H, Murali R, Potdar AA, Wolf AJ, Botwin GJ, Khrom M, International IBD Genetics Consortium, Ananthakrishnan AN, Faubion WA, Jabri B, Lira SA, Newberry RD, Sandler RS, Sartor RB, Xavier RJ, Brant SR, Cho JH, Duerr RH, Lazarev MG, Rioux JD, Schumm LP, Silverberg MS, Zaghiyan K, Fleshner P, Melmed GY, Vasiliauskas EA, Ha C, Rabizadeh S, Syal G, Bonthala NN, Ziring DA, Targan SR, Long MD, McGovern DPB, Michelsen KS.   +44 more
europepmc   +3 more sources

Case Report: Combined Liver-Kidney Transplantation to Correct a Mutation in Complement Factor B in an Atypical Hemolytic Uremic Syndrome Patient. [PDF]

Front Immunol, 2021
López-Trascasa M, Alonso-Melgar Á, Melgosa-Hijosa M, Espinosa-Román L, Lledín-Barbancho MD, García-Fernández E, Rodríguez de Córdoba S, Sánchez-Corral P.   +7 more
europepmc   +3 more sources

Complement Factor B Production in Renal Tubular Cells and Its Role in Sodium Transporter Expression During Polymicrobial Sepsis. [PDF]

Crit Care Med, 2016
Li D, Zou L, Feng Y, Xu G, Gong Y, Zhao G, Ouyang W, Thurman JM, Chao W.   +8 more
europepmc   +2 more sources

Splenic RNA and MicroRNA Mimics Promote Complement Factor B Production and Alternative Pathway Activation via Innate Immune Signaling. [PDF]

J Immunol, 2016
Zou L, Feng Y, Xu G, Jian W, Chao W.
europepmc   +2 more sources